Clinically, ongoing research by Levitt et al. [35] demonstrated that psoriasis patients treated with biologic agents targeting IL-17, IL-23, IL-12/23, or TNF-α exhibited a nearly 50% reduction in dementia incidence compared with those receiving conventional systemic therapy, suggesting that sustained cytokine inhibition may mitigate systemic and neuroinflammatory cascades contributing to cognitive decline [35]. Here, IL17A is linked to psoriasis.